Lapatinib Suppresses HER2-Overexpressed Cholangiocarcinoma and Overcomes ABCB1– Mediated Gemcitabine Chemoresistance

BACKGROUND: Recent breakthroughs in cholangiocarcinoma (CCA) genomics have led to the discovery of many unique identifying mutations, of which HER2 has been found to be overexpressed specifically in cases of extrahepatic CCA. However, whether or not lapatinib (an oral tyrosine kinase inhibitor selec...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Zhiqing, Guo, Zhiying, Liu, Jiaxing, Chen, Yu-Ann, Lu, Qian, Zhang, Ping, Hong, Lili, Wang, Yunfang, Dong, Jiahong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033256/
https://www.ncbi.nlm.nih.gov/pubmed/35463361
http://dx.doi.org/10.3389/fonc.2022.860339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033256/
https://www.ncbi.nlm.nih.gov/pubmed/35463361
http://dx.doi.org/10.3389/fonc.2022.860339

Ejemplares similares